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Diabetes is a common comorbid condition among colorectal cancer (CRC) patients, yet 
its effects in CRC outcomes, particularly stage at diagnosis, risk of death and variations by 
diabetes severity (complications vs no complications) and Hispanic ethnicity have not been 
adequately studied. The purpose of this study was to investigate the association between pre-
existing T2DM and advanced stage at diagnosis in elderly patients with CRC; to examine 
whether diabetes is an independent predictor of poor survival from all-cause and CRC-specific 
mortality; to assess whether variations exist by diabetes severity and to analyze the outcomes for 
the Hispanic group.  
The Surveillance Epidemiology and End Results (SEER)-Medicare linked datasets were 
used to extract data on Medicare beneficiaries 67 years and older residing in the SEER areas who 
were diagnosed with CRC between 2002 and 2011. These datasets provided clinical, 
demographic, administrative claims and enrollment information for the Medicare population 
under study.  Pre-existing T2DM was ascertained from the Medicare inpatient and outpatient 
claims using validated algorithms.  
The association of advanced stage at diagnosis with CRC was compared between pre-
diabetic and non-diabetic patients using logistic regression. All-cause and CRC cause-specific 
death risk differences were compared using Cox proportional hazards model and hazard ratios 
were compared in relation to prior T2DM diagnosis and diabetes severity status. All models were 
adjusted for relevant factors including demographic characteristics such as age, sex, marital 
status, race/ethnicity and census poverty level. Clinical factors adjusted for included comorbidity 
score, grade, histology, stage at diagnosis, year of diagnosis and cancer registry.  
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The analyses included 93,710 CRC patients. Among the study population, 22,155 (24%) 
had diabetes prior to CRC diagnosis and, of these, 17% had diabetes-related complications 
(neuropathy, nephropathy, retinopathy or peripheral circulatory disorders).  Diabetic patients 
were more likely to be older, male, non-White, lived in medium to high poverty level areas, had 
at least one or more comorbidities, and had tumors in the proximal colon. From the regression 
models, diabetes was not significantly associated with CRC advanced stage at diagnosis (odds 
ratio (OR) = 0.986; 95% confidence interval (CI) = 0.953-1.02 for diabetes without 
complications and OR = 0.963; 95% CI = 0.897-1.034 for diabetes with complications). Similar 
results were observed for Hispanic patients. Overall mortality was significantly higher among 
diabetic patients compared to non-diabetic patients (hazard ratio (HR) = 1.198; 95% CI = 1.169-
1.228). The results were more pronounced for diabetes with complications (HR = 1.467; 95% CI 
= 1.339-1.538). Patients who had diabetes with complications were 16% more likely to die of 
colorectal cancer compared to patients without diabetes in the fully adjust model (HR = 1.162; 
95% CI = 1.083-1.247). Among Hispanics, diabetes was an independent predictor of poor 
survival from all-cause mortality but not CRC specific of death. 
This study used population-based data and the findings indicate that pre-existing diabetes 
contributes to poorer overall survival in patients with colorectal cancer and increased mortality 
from CRC in diabetes with complications. Because these diseases are more prevalent among the 
elderly, this group is more likely to have both diseases at the same time and more clinicians will 
need to develop care plans that are interdisciplinary and take into consideration the added burden 
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CHAPTER 1: INTRODUCTION 
Colorectal cancer (CRC) and type 2 diabetes mellitus (T2DM) are major causes of 
morbidity and death in the Unites States. Both diseases are preventable through screening and 
lifestyle changes.  CRC and T2DM share many common risk factors that characterize the 
Western lifestyle including physical inactivity; obesity, especially, abdominal adiposity; and 
unhealthy diet (Chan, Rimm, Colditz, Stampfer, & Willett, 1994; Fung, Schulze, Manson, 
Willett, & Hu, 2004; Giovannucci et al., 1995; van Dam, Rimm, Willett, Stampfer, & Hu, 2002).  
A major characteristic of T2DM is hyperinsulinemia which is related with many chronic 
diseases such as cardiovascular diseases and carcinogenesis (Alberti et al., 2009; Shanik et al., 
2008).  Researchers have found that diabetes is an independent factor in carcinogenesis for many 
common cancers including breast, bladder, liver, pancreatic, and CRC among others (Coughlin, 
Calle, Teras, Petrelli, & Thun, 2004).  
The association of diabetes and increase of CRC risk has been explored by many 
researchers, however, studies assessing the relationship of pre-existing T2DM and CRC stage at 
diagnosis are lacking. Stage at diagnosis is an important determinant of treatment course and 
prognosis. Understanding how diabetes status affects earlier CRC diagnosis would help 
clinicians improve recommendations of diabetes control and CRC screening. Moreover, the 
association of diabetes and risk of unfavorable survival by diabetes severity (presence of 
complications), are inadequately studied.  
Colorectal cancer and diabetes are experienced differently among racial and ethnic 
groups. Among Hispanics, colorectal cancer is the second most common diagnosed cancer 
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(compared to third among non-Hispanic Whites) (Siegel et al., 2015). Although incidence and 
mortality rates of colorectal cancer are slightly lower in Hispanics compared to non-Hispanic 
Whites, Hispanics are more likely to be diagnosed at an advanced stage of disease and they 
suffer from slightly lower cancer-specific 5-year survival (Siegel et al., 2015). Moreover, there is 
a trend of increased CRC incidence among young Hispanics (Wang et al., 2017). On the other 
hand, Hispanics experience higher prevalence of diabetes in relation to their White counterparts 
and the incidence trend is upwards over time (Schiller, Lucas, Ward, & Peregoy, 2012). 
Understanding how diabetes affects prognosis of Hispanic CRC patients is crucial to reduce 
morbidity and mortality among this growing population.  
The purpose of this study is to investigate the association between pre-existing T2DM 
and risk of advanced CRC stage at diagnosis and poorer survival in a population of patients 67 
years and older who were diagnosed with CRC in one of the areas covered by the Surveillance, 
Epidemiology and Ends Results (SEER) program. Among CRC patients, stage at diagnosis was 
compared between those who have T2DM prior to CRC diagnosis and those without a T2DM 
diagnosis. CRC survival differences for overall mortality and CRC cause-specific mortality by 
diabetes status and diabetes severity status were examined. Variations in outcomes for the 
Hispanic group were analyzed.  
Data was obtained retrospectively from the SEER-Medicare linked data files. These files 
contain clinical and demographic information as well as claims data for the Medicare 
beneficiaries who have a cancer diagnosis. The Medicare program managed by the Centers for 
Medicare and Medicaid Services records claims of services received by Medicare beneficiaries 
and provide a continuum of care from enrollment until patients’ death regardless of patients’ 
place of residence.  
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To our knowledge, this is the first study to assess the association of pre-existing T2DM 
and colorectal cancer stage at diagnosis and survival differences by diabetes severity with a focus 
on elder Hispanics using a population-based dataset. Findings from this study will bring more 
evidence to the increasing need to prevent and control diabetes especially in a population that is 
disproportionately affected by this disease such as the Hispanic population.  
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CHAPTER 2: BACKGROUND AND SIGNIFICANCE 
Section 1: The burden of colorectal cancer (CRC) and type 2 diabetes mellitus (T2DM) 
CRC in the United States 
CRC characteristics  
Colorectal cancer is cancer that forms in the colon or rectum area of the digestive system. 
CRC starts as abnormal growths called polyps that form in the inner wall of the colon or rectum. 
These polyps can be removed early before they develop into cancer preventing CRC. The 
majority of CRC cancers are adenocarcinomas (Centers of Disease Control and Prevention, 
(CDC), 2015). 
CRC risk factors 
Definitive etiological factors causing CRC have not been identified, however, there are 
several risk factors that are related to developing the disease. Incidence of CRC is higher among 
the elderly; over 90% of CRC patients are over 50 years of age. Additional risk factors include: 
inflammatory bowel disease; Crohn’s disease, or ulcerative colitis; personal or family history of 
CRC or colorectal polyps; and genetic syndromes (familial adenomatous polyposis (FAP) or 
Lynch syndrome) (Jaruvongvanich, Sanguankeo, Wijarnpreecha, & Upala, 2017; Jasperson, 
Tuohy, Neklason, & Burt, 2010).   
Many lifestyle factors have been linked to CRC. Heavy alcohol consumption is 
associated with a 60% increase in getting CRC compared to no or light consumption (relative 
risk (RR) = 1.56, 95% confidence interval (CI) = 1.42–1.70) (Huxley et al., 2009). The risk 
associated with alcohol consumption increases particularly in individuals with mismatch repair 
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gene mutation (Ghazaleh Dashti et al., 2017). Other lifestyle risk factors include smoking, 
obesity and high meat intakes (Huxley et al., 2009; Wu, Paganini-Hill, Ross, & Henderson, 
1987). Obesity and weight gain association with CRC differs by gender; in women, weight gain 
in early life is a determinant of CRC risk more so than later life obesity. However, in men, it is 
the later in life obesity that increases the risk for CRC (Kim & Giovannucci, 2017). 
Contrary to factors that increase risk of CRC, physical activity is protective against 
colorectal cancer. In a review study, it was found that highly active individuals benefited from a 
20% lower risk of CRC compared with individuals with lower physical activity levels (RR = 
0.81, 95% CI = 0.77–0.86) (Huxley et al., 2009).  
CRC screening 
CRC can be prevented with screening tests that remove polyps or diagnosed early when 
treatment is most effective (US Preventive Services Task Force, 2015). CRC screening tests 
include high-sensitivity fecal occult blood test (FOBT), flexible sigmoidoscopy, and 
colonoscopy. Recommendations and guidelines on screening use, frequency and appropriate age 
are set by the U.S. Preventive Services Task Force. On a population level, rates of new cases of 
CRC have been steadily declining which is likely associated with higher uptake of CRC 
screening. For instance, recent national surveys show that colonoscopy uptake increased from 
19% in 2000 to 55% in 2013 among adults aged 50 to 75 years of age (Siegel, Miller, & Jemal, 
2016a). Screening uptake is generally higher among women than men particularly for 
colonoscopy, conversely, screening is lower among Hispanics compared to non-Hispanics 




CRC is the third most common cancer in both men (after prostate and lung cancer) and 
women (after breast and lung cancer) in the United States (Siegel, Miller, & Jemal, 2016b). In 
2016, there were 134,490 projected new cases (70,820 cases in men and 63,670 in women) and 
an estimated 49,190 total deaths due to CRC. Colorectal cancer is the second leading cause of 
cancer death among men aged 60 to 79 and third leading cause of cancer death among women in 
the same age group (Siegel et al., 2016a).   
Men experience higher CRC incidence compared to women particularly at older age (rate 
ratio = 1.39, P <0.05). Incidence rates differ by race and ethnicity; Blacks have highest incidence 
compared to Whites and other races. On the other hand, Hispanics have historically had lower 
incidence in relation to their White counterparts (Rim, Seeff, Ahmed, King, & Coughlin, 2009). 
These racial disparities are more pronounced among individuals 65 years or younger.  
Overall, CRC incidence has been declining for both men and women at about 3% per 
year from 2003 through 2012 which is largely attributed to increased uptake of screening and 
removal of precancerous lesions (Cress, Morris, Ellison, & Goodman, 2006). Distal colon cancer 
is more prevalent among elder men, while distal tumors are more prevalent in younger women 
(Devesa & Chow, 1993; Murphy et al., 2011). 
Stage at diagnosis and survival 
Stage at diagnosis is highly associated with prognosis in malignancies (Siegel et al., 
2016a). Among CRC patients, 39% are diagnosed at an early stage and 20% are diagnosed at an 
advanced stage. Overall, the five-year relative survival rate for CRC is 65%; however, survival 
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drops considerably form 90% in patients diagnosed at a localized stage to only 13% for distant 
stage (Siegel et al., 2016b).   
Type 2 Diabetes (T2DM) in the United States 
T2DM characteristics  
T2DM, or non-insulin dependent diabetes, is a form of diabetes that starts primarily in 
adults, although, children and adolescents are increasingly affected with this disease. T2DM is 
characterized by imbalance between the body’s sensitivity to insulin and insulin secretion by the 
pancreatic beta cells. T2DM is usually preceded with insulin resistance (Martin et al., 1992). 
This occurs when body cells, particularly, muscle, liver, and fat cells do not use insulin properly 
resulting in blood glucose build up. As a result, the beta cells produce more insulin; however, 
this increase in insulin secretion causes the beta cells to gradually lose the ability to secrete the 
hormone to compensate for insulin resistance (Centers for Disease Control and Prevention, 2011; 
DeFronzo, 1992).  
T2DM risk factors 
Weight gain and obesity, particularly high waist circumference, increase the risk of 
T2DM. Other risk factors include older age; family history of diabetes; Western diet high in 
processed foods; low physical activity; a previous diagnosis of gestational diabetes; glucose 
intolerance; and particular racial/ethnic groups (Chan et al., 1994; Fung et al., 2004; Haffner, 




Diabetes diagnosis indicates blood glucose levels above normal (fasting plasma glucose 
of 126 mg/dL or above). According to the 2012 National Health and Nutrition Examination 
Survey estimates, diabetes mellitus affects nearly 10% of Americans representing a total of 29.1 
million people of all ages (Centers for Disease Control and Prevention, 2014). Every year, about 
1.4 million people are newly diagnosed with diabetes. In the US, diabetes is the seventh leading 
cause of death (National Center for Health Statistics, (US, 2016). From these most recent 
estimates, almost 30% of diabetics do not know they have diabetes. Moreover, 86 million 
Americans aged 20 years or older have prediabetes and, therefore, are at higher risk of 
developing the disease (American Diabetes Association, 2014).  
Diabetes demographics 
Diabetes affects more men than women and is higher among elderly people with a 
prevalence of 25.9% seniors diagnosed. Minorities have higher prevalence of diabetes compared 
to Non-Hispanic whites; however, the prevalence varies by minority group. For instance, 24.1% 
of Southern Arizona American Indians have been diagnosed with diabetes compared to only 6% 
of Alaska Natives. (American Diabetes Association, 2014; Schneiderman et al., 2014) 
T2DM complications 
Uncontrolled diabetes may result in serious complications. Diabetic patients are at 2 to 4 
fold increased likelihood of developing macrovascular complications (cardiovascular and 
coronary heart disease) (Brownlee, 2001; Feldman, 2003). Moreover, nearly all individuals with 
diabetes will eventually be affected by some or all diabetes-specific microvascular complications 
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including diabetes retinopathy, diabetic nephropathy and diabetic neuropathy (Brownlee, 2001). 
In the US, 32% of diabetic patients have diabetic retinopathy (Wong et al., 2006) and 40% 
develop diabetic nephropathy. Almost 50% of all incident cases of end-stage renal disease 
(ESRD) are attributed to kidney-related complications among diabetic patients (National 
Institutes of Health, 2010). Other complications associated with diabetes include diabetic 
neuropathy with peripheral nerve dysfunction which is present in more than half of diabetic 





Section 2: Pathophysiology of T2DM and CRC link 
Insulin resistance & hyperinsulinemia 
The early stages of T2DM are characterized with insulin resistance. Insulin resistance 
indicates impaired hepatic and muscle tissue sensitivity to insulin. The inability of insulin to 
stimulate use and storage of glucose causes diminished glucose uptake by the liver and muscle 
tissues. This insulin dysfunction promotes pancreatic beta cells to increase their insulin secretion 
to compensate for the increased blood circulating glucose inducing a state of hyperinsulinemia 
(DeFronzo, 1992). 
Insulin, IGF-1, and colorectal malignancy  
Insulin has growth factor properties on normal and carcinogenic colonic cells in vitro 
(Godsland, 2010; Kabat et al., 2012; Koenuma, Yamori, & Tsuruo, 1989; Watkins, Lewis, & 
Levine, 1990). Insulin stimulating action is mediated through hepatic growth hormone receptors. 
In turn, growth hormone regulates the production of insulin-like growth factor 1 (IGF-1) in the 
liver (Jones & Clemmons, 1995). Another mechanism by which insulin increases levels of free 
IGF-1 is inhibition of insulin growth factor binding proteins (IGFBP-1 and IGFBP-2) (Nam et 
al., 1997; Ooi, Tseng, Tran, & Rechler, 1992). 
Insulin-like growth factor 1 is a polypeptide produced by the liver and acts similarly as 
insulin (Rinderknecht & Humbel, 1978). IGF-1 is involved in cellular growth and inhibition of 
apoptosis and therefore is associated with increased carcinogenesis risk in many types of cancers 
(Aaronson, 1991; Grimberg & Cohen, 2000). IGF-1 is particularly involved in the pathogenesis 
of CRC. IGF-1 receptors (IGF-1R) are present in colon epithelial cells with high level binding 
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and potential influence on CRC pre-malignancy (Laburthe, Rouyer-Fessard, & Gammeltoft, 
1988). Moreover, the majority of CRC tumor cells express IGF-1R which resembles insulin 
receptors (Hakam et al., 1999; Pollak, Perdue, Margolese, Baer, & Richard, 1987; Weber et al., 
2002). 
In vivo and in vitro studies on animal models have shown that human insulin and IGF-1 
stimulate malignant cells proliferation in mice with colon adenocarcinoma in a dose-dependent 
manner. These growth factors stimulate the DNA synthesis of malignant cells particularly the 
high-metastatic tumor cells. Consequently, growth factors have the ability to augment the 
formation of tumor metastasis (Koenuma, Yamori, & Tsuruo, 1989). 
High fasting glucose and CRC risk 
In addition to hyperinsulinemia and IGF-1 etiological pathways, hyperglycemia is also 
related with increased CRC risk. Investigators found that patients who had the highest level of 
fasting glucose had a remarkable two fold increased risk of CRC (Schoen et al., 1999). Likewise, 
uncontrolled hyperglycemia, signaled by a high hemoglobin A1c levels, significantly increases 
risk of CRC (Stocks et al., 2008). 
Epidemiologic studies of T2DM as a risk factor for CRC 
The plausibility of the association between diabetes and CRC has been explored through 
epidemiological studies. Researchers have used observational studies to investigate diabetes 
mellitus as a risk factor for CRC risk and mortality in different settings and populations.  
In a large prospective cohort, the National Health and Nutrition Survey I, Steenland, 
Nowlin, and Palu (1995) analyzed diabetes as a risk factor for multiple cancers. Although they 
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found an overall increased risk for all cancers in diabetics (Odds ratio (OR) = 1.38; 95% 
confidence interval (CI): 1.00-1.91), the increased risk for CRC did not reach significance in 
both men and women (OR = 1.43; 95% CI:  0.61-3.31 and OR = 1.4; 95% CI: 0.61-3.10 
respectively). Flood, Strayer, Schairer, and Schatzkin, (2010) compared CRC risk in a cohort of 
women with and without diabetes. They found diabetic women to have increased risk of CRC 
(multivariate relative risk (RR) = 1.60, 95% CI 1.18–2.18) with a time-dependent association.  
Diabetes exposure has been studied as part of the metabolic syndrome.  In the Physicians’ 
Health Study, men with diabetes had a 50% increased risk of CRC compared to men without 
diabetes (RR = 1.50; 95% CI: 1.1-2.0) (Sturmer et al., 2006). Similarly, Ahmed, Schmitz, 
Anderson, Rosamond, and Folsom (2006) observed a 39% increase in CRC risk in diabetic 
participants (RR = 1.39; 95% CI: 1.0-1.8). In addition to CRC risk, diabetes is implicated in 
increased CRC mortality. In a large prospective cohort study, Coughlin and colleagues (2004) 
found diabetes to be associated with fatal colon cancer in both men and women (RR = 1.20; 95% 
CI: 1.06-1.37) and RR = 1.24, 95% CI: 1.07, 1.43 respectively). Whaheed, Azad, S. Waheed, and 
Yeh (2014) explored survival disparities among adults with CRC stratified by race. They found 
that diabetes is an effect modifier in the relationship between race and CRC survival.  
Women from the Iowa Women’s Health Study had a significant increased relative risk of 
CRC in women with T2DM in relation to women without T2DM (RR = 1.4; 95% CI: 1.1-1.8), 
particularly for the proximal colon subsite (Limburg et al., 2005). Likewise, type 2 diabetic 
women in the Nurses’ Health Study had a 43% increased risk of CRC compared to non-diabetics 




Section 3: CRC and T2DM among Hispanics 
Hispanics are the second largest racial/ethnic minority group in the US. It is estimated 
that this group will continue growing and double by 2050 (Ennis, Rios-Vargas, & Albert, 2015). 
Cancer disparities are documented for Hispanics based on low levels of health insurance, higher 
poverty and different exposures in terms of behavioral and environmental factors that contribute 
to disproportionate cancer outcomes. The experience of cancer varies markedly between 
Hispanics and Non-Hispanic Whites and also among Hispanic subgroups (Mexican, Puerto 
Rican, Salvadoran, Cuban, and Dominican). These variations are driven by lifestyle patterns and 
cancer-causing exposures particularly obesity and diabetes (National Center for Health Statistics, 
2016; Ward et al., 2004).   
CRC in Hispanics 
Among Hispanics, colorectal cancer is the second most common cancer among men and 
the third most common diagnosed cancer in women (Siegel et al., 2015). In 2015, the estimated 
new cases of CRC were 6,400 in men and 5,300 in women. In same year, it was estimated that 
CRC was the cause of 12% of cancer deaths in Latino males and 9% in Latina females (Siegel et 
al., 2015). About 5-10% of CRC in Hispanics is hereditary and is associated with familial 
adenomatous polyposis (FAP) and Lynch Syndrome (LS) (Cruz-Correa et al., 2017). Although 
CRC is higher among older Hispanics, new trends show that CRC incidence is increasing among 
younger patients (Wang et al., 2017). 
CRC incidence and death in Hispanics is slightly lower than among Non-Hispanic Whites 
(NHW), however, variations exist among Hispanic subgroups (Pinheiro et al., 2009). Although 
incidence and mortality rates of CRC are slightly lower in Hispanics compared to NHW, 
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Hispanics are slightly more likely to present with distant stage disease (Siegel et al., 2015). 
Hispanics with CRC have unfavorable five-year cancer-specific survival in relation to NHW 
particularly among men. Compared to other Hispanic subgroups, Cubans have the highest CRC 
mortality rates (Pinheiro et al., 2017). 
CRC screening uptake is overall modest among all racial ethnic groups, nonetheless, 
Hispanics have some of the lowest rates. The use of CRC screening is noticeably lower in 
Hispanics (44.9%) compared to NHW (60.5%). The proportion of screening is even lower 
among uninsured Hispanics at only 11%. By Hispanic subgroup, Dominicans and Cubans have 
the lowest screening rates (below 40%), while Puerto-Ricans have the highest screening 
prevalence at 56% (Siegel et al., 2015). 
Hispanics suffer disproportionately from CRC risk factors, particularly obesity (Eheman 
et al., 2012). The prevalence of obesity in adult Hispanic females is 45.2% compared to 33.3% in 
NHW females and 40.9% in Hispanic males compared to 32.8% in NHW males (Siegel et al., 
2015). Although the prevalence of obesity has stabilized in more recent years for NHW, it is 
rapidly increasing for Mexican men (Fryar, Carroll, & Ogden, 2012). 
Diabetes in Hispanics 
Diabetes affects 16.9% of Hispanics living in the U.S. (compared to 7.6% in NHW) 
(Schneiderman et al., 2014). This prevalence increases to 22.4% among obese patients. Other 
authors found that within Hispanic sub-groups, diabetes prevalence varies considerably; it is 
highest among Mexicans, Dominicans and Puerto Ricans (at 18%) and lowest among South 
Americans at 10.2%. Diabetes prevalence in Hispanics is positively related to length of US 
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residence and it continues to increase even though it has remained stable nationally (Geiss et al., 
2014).  
In addition to high prevalence rates of diabetes, Hispanics suffer from inadequate 
education about the disease. Additionally, Hispanic patients have low health insurance coverage 
(52.4%) (Schneiderman et al., 2014). Moreover, Hispanics are more likely to have poorer 
diabetes control (29.8%) compared to NHW (16.6%) (National Center for Health Statistics, 
2016). 
Diabetes is the number four killer for both males and females in Hispanics vs number 
seven in Whites. Similarly, death from this disease is higher among Hispanics (25.1%) compared 




Section 4: Study rationale and significance 
Study rationale 
A review of the current literature shows that diabetes increases the risk of developing 
colorectal cancer; however, studies assessing whether pre-existing T2DM is associated with 
advanced stage at diagnosis of CRC using population-based datasets are lacking. CRC prognosis 
depends largely on stage at diagnosis with advanced stage leading to the poorest survival rates. 
Understanding how diabetes status affects earlier CRC diagnosis would help clinicians improve 
recommendations of diabetes control and CRC screening. 
Development of diabetes-related complications among diabetic patients is very likely, 
yet, the effect of diabetes complications on survival outcomes in CRC patients has not been fully 
examined. An analysis of how diabetes with and without complications is likely to affect 
survival is paramount to inform clinical decisions in terms of CRC management and treatment. 
A rising trend of diabetes combined with suboptimal rates of CRC screening in Hispanics 
poses considerable risks of unfavorable health outcomes. The increasing burden of diabetes in 
Hispanics may halt or even reverse the recent gains in terms of reduction in CRC incidence 
among Hispanics. Further, the importance of this shift may be even stronger in the instance that 
diabetes is related to increased risk of late stage at diagnosis of CRC. In this case, evidence-
based action is needed.  
Significance to Public Health 
This study can help make an effective change in the health of CRC patients. Results from 
this investigation will orient public health interventions to a more aggressive focus on colorectal 
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screening in higher risk populations with diabetes. Tailored messages and programs to special 




CHAPTER 3: METHODS 
Section 1: Study purpose and hypotheses 
Study purpose 
The purpose of this study is to investigate the association between pre-existing T2DM 
and advanced CRC stage at diagnosis; the association of pre-existing diabetes (with and without 
complications) and higher risk of poorer overall and CRC-specific mortality compared to 
patients without diabetes; and whether variations exist for the Hispanic subgroup. This study 
used data from Surveillance Epidemiology and End Results (SEER)-Medicare program. The 
cohort consisted of Medicare beneficiaries 67 years and older diagnosed with CRC between 
2002 and 2011. These datasets provide clinical, demographic, administrative claims and 
enrollment information for the Medicare population under study. Pre-existing T2DM is 
ascertained from the Medicare inpatient and outpatient claims using validated algorithms. 
Hypotheses 
The main hypotheses examined under this study are: 
Hypothesis 1: 
 H0: There is no difference in the odds of advanced stage at diagnosis among CRC 
patients who have pre-existing diabetes compared to those who do not have diabetes 
 H1: The odds of advanced stage at diagnosis among CRC patients are higher in subjects 
with diabetes compared to those without diabetes 
o Outcome variable: CRC stage at diagnosis 
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o Independent variable: pre-existing diabetes 
o Study group: overall study population 
Hypothesis 2: 
 H0: There is no difference in risk of overall mortality in CRC patients with pre-existing 
diabetes, with and without complications, compared to those without diabetes 
 H1: Risk of all-cause mortality in CRC patients is higher among those with diabetes with 
and without complications, compared to those without diabetes 
o Outcome variable: overall mortality 
o Independent variable: pre-existing diabetes, with and without complications 
o Study group: overall study population 
Hypothesis 3: 
 H0: There is no difference in risk of colorectal cancer-specific mortality in patients with 
pre-existing diabetes, with and without complications, compared to those without 
diabetes 
 H1: Risk of colorectal cancer-specific mortality is higher in CRC patients with diabetes, 
with and without complications, compared to those without diabetes 
o Outcome variable: colorectal cancer-specific mortality 
o Independent variable: pre-existing diabetes, with and without complications 





 H0: There is no difference in risk of overall and cause-specific mortality in Hispanic 
CRC patients with pre-existing diabetes, with diabetes with and without complications,  
compared to those without diabetes 
 H1: Risk of all-cause and cancer-specific mortality is higher in Hispanic CRC patients 
with diabetes, with and without complications, compared to those without diabetes 
o Outcome variable: overall mortality 
o Independent variable: pre-existing diabetes, with and without complications 
o Study group: Hispanic subgroup  
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Section 2: Data source 
Medicare Program 
The Medicare program under the Centers of Medicaid and Medicare Services (CMS) is a 
Federal health insurance plan that offers health insurance for qualifying elders 65 years and older 
and select disabled adults. Eligible beneficiaries are entitled for the Part A plan which covers 
hospitalizations, hospice, home health, and skilled nursing facilities. Beneficiaries may purchase 
a supplemental medical insurance under Part B to cover physician and outpatient care. Since 
2006, beneficiaries may purchase medication coverage policy under Part D. Medicare enrollees 
must have both Part A and Part B to be eligible for full Fee For Service (FFS) benefits. 
Approximately 94% of enrollees have both Part A and Part B (Centers for Medicare & Medicaid 
Services, 2013). 
The SEER Program 
Since its inception in the 70s, the National Cancer institute’s Surveillance, Epidemiology 
and End Results (SEER) program has been collecting data on every case in the covered areas 
with a case ascertainment level as high as 95%. The SEER cancer registries collect data under 
rigorous standards to maintain accuracy and timeliness. The program includes 20 U.S. 
geographic areas covering about 28% of the domestic population (Surveillance, Epidemiology, 
and End Results (SEER) Program, 2013). Data from this program is used extensively across the 
spectrum of the research community as well as health officials and community members. Data 
from the SEER program allow to generate periodic cancer statistics at a population level and 




SEER-Medicare linked data files 
The files contain clinical and demographic information about Medicare beneficiaries with 
cancer. Researchers have used these data to conduct studies about a variety of outcomes 
including cancer risk factors, cancer treatment costs, and cancer survival determinants. The 
SEER files provide clinical, demographic and cause of death information for persons with cancer 
while the Medicare files provide detailed claims of services received by Medicare beneficiaries 
and a continuum of care until patients’ death. The SEER and Medicare data are linked every two 
years and each linkage successfully matches 93 percent of persons age 65 and older SEER cases 
to their Medicare enrollment and claims files (Warren, Klabunde, Schrag, Bach, & Riley, 2002).  
The SEER-Medicare datasets have been used extensively by researchers in all fields. 
There have been over 1400 manuscripts published that used these data in nearly 250 national and 
international journals some of those journals include JAMA, Lancet oncology, the Journal of 
American Heart Association, European Journal of Cancer, American Journal of Public Health. 
The top 3 journals with highest number of publications using the SEER-Medicare are Cancer, 




Section 3: Data files  
The SEER-Medicare data refer to a series of files. The SEER data are included in one of 
the files while the Medicare claims data are found in the remaining files for each specific type of 
service (e.g. hospital, physician, outpatient, medication, home health, etc.). This study utilized 
the following files: 
The Patient Entitlement and Diagnosis Summary file (PEDSF)  
The PEDSF includes both demographic and clinical information on each person such as 
date of birth, date of death, sex, race, and state of residence, date of diagnosis, first course of 
treatment, survival in months, stage at diagnosis, source of diagnosis, etc. It also contains 
variables from the Medicare enrollment file such as Medicare eligibility and reason for 
eligibility, enrollment status in health maintenance organization (HMO), the level of match of 
the birth date and the death date between SEER and Medicare, etc. 
The Medicare Provider Analysis and Review (MEDPAR)  
The MEDPAR file includes long, short stay and skilled nursing facility claims for part A 
beneficiaries. Each time a patient is admitted to an inpatient facility, a claim is recorded.  
The Outpatient Claims file  
Claims from institutional outpatient providers are found in the Outpatient Claims file. 
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Section 4: Study population and design 
Study Population 
The cohort under study includes elderly patients aged 67 years and older diagnosed with 
CRC between 2002 and 2011 in one of the SEER area. CRC cases are identified in the PEDSF 
which has one row per patient. Only patients who have CRC cancer listed as primary cancer are 
considered for the analysis. Patients are de-identified and each one is given a random patient ID 
that can be used to link with the Medicare claims datasets. 
Study design 
The SEER-Medicare datasets allow the use of different observational study designs. The 
SEER program collects data on all incident cancers in the SEER areas with a 95% case 
ascertainment. The cancer registries actively follow cancer patients and record death/alive status 
at the end of each submission. Similarly, CMS reports information on all beneficiaries from 
entitlement to death regardless of place of residence.  
The association of pre-existing T2DM and CRC stage at diagnosis is analyzed using a 
cross-sectional design. All cancer cases that fit the inclusion and exclusion criteria are assessed 
at a single point in time with stage at diagnosis as the outcome and pre-existing T2DM as the 
exposure. On the other hand, cancer cases are followed retrospectively using a retrospective 
cohort design to examine the effect of T2DM diagnosis on CRC survival. 
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Section 5: Analytic variables and inclusion criteria 
This study requires the use of variables for the analytical models and other variables to 
build the study population file. Moreover, many variables will need to be recoded (age, 
histology, stage, race, marital status, etc.). The Medicare enrollment file is used to restrict the 
study population to those who have Part A and Part B and were not enrolled in Health 
Management Organizations (HMO) 24 month prior to CRC diagnosis. On the other hand, 
Medicare claims files are used to ascertain pre-existing diabetes and comorbidities.  
Medicare entitlement and enrollment  
Patients can become eligible for Medicare coverage through age (65 years and older), 
disability (any age) or End Stage Renal Disease (ESRD) (any age). Patients remained in the 
analysis file only if they were Medicare entitled by age. Patients entitled through disability or 
ESRD were excluded. 
CMS records Medicare entitlement for each beneficiary each month of a calendar year. 
Patients are included if they have continuous Medicare part A and part B entitlement and no 
HMO entitlement 24 months prior to CRC diagnosis date and three months after.  
Demographic variables  
Age  
Age was restricted to 67 years or older at the time of CRC diagnosis. The exclusion of 
patients younger than 67 years old allows to have at least two years of Medicare claims history 
for each patient. Three age groups were created (67-75, 76-85, and 85 years old and older). 
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Marital status  
Marital status was recoded to: single, married, separated/divorced, widowed, and 
unknown.  
Race Ethnicity  
The SEER program tracks race and ethnicity separately. The race variable was combined 
with the Hispanic ethnicity variable which tracks whether a patient is of Hispanic origin. Patients 
of any race that were flagged as having Hispanic origin were grouped as Hispanics irrespective 
of race. The combined variable included these race/ethnic groups: White non-Hispanic, Black 
non-Hispanic, Hispanic, non-Hispanic Asian Pacific Islander, and non-Hispanic American 
Indians/ Alaska Natives.  
Census tract median income 
The SEER program does not record socio-economic status (SES) at the individual level, 
therefore, an ecological measure is used to indicate SES based on census tract. Each patient in 
the SEER file was assigned a census tract ID based on the year of CRC diagnosis which then was 
used to link to the Census Tract File. This file used Census 1990, Census 2000 and the American 
Community Survey (ACS) 2008-2012. The variable median household income for census tract 
was grouped into quartiles (low, medium, medium high and high poverty level). 
Clinical variables 
The PEDSF file contains the clinical information on CRC patients such as stage, 
morphology, histology and tumor behavior. Patients were restricted to those who have CRC 
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listed as first primary diagnosis sequence 0 and 1 and those with malignant tumors (excluded 
benign, borderline and in situ). Patients were also excluded if the month of diagnosis was 
missing and if they were diagnosed at autopsy or death certificate (src1=6 or src1=7); these 
patients usually do not have information on stage at diagnosis and other clinical variables and; 
therefore, do not have the information needed for the analysis. The analysis was also restricted to 
patients diagnosed in 2002 and onward.  
Tumor site 
Colon tumor sites included: ascending, transverse, descending and sigmoid; hepatic and 
splenic flexure and other colon sites not otherwise specified (NOS). Patients diagnosed in sites 
other than colon or rectum were excluded. Table 1 shows the International Classification of 
Diseases for Oncology 3rd edition (ICD-O-3) site codes used to select the patients with 
colorectal cancer. The CRC site variable was then recoded to four categories: proximal colon 









C18.2 Ascending colon; Right colon 
C18.3 Hepatic flexure of colon 
C18.4 Transverse colon 
C18.5 Splenic flexure of colon 
C18.6 Descending colon; Left colon 
C18.7 Sigmoid colon 
C18.8 Overlapping lesion of colon 
C18.9 Colon, NOS 
Rectosigmoid junction 
C19.9 Rectosigmoid junction 
Rectum 
C20.9 Rectum, NOS 





Tumors have different histological types based on their microscopic composition. Staging 
of tumors relies predominantly on histology type which in turn determines the course of 
treatment for each cancer patient. Coding histology types follows The International 
Classification of Diseases for Oncology, Third Edition (ICD-O-3) standards of reference. In this 





Tumor grade is used extensively in patient treatment course and prognosis. Grade was 
grouped into: Grade I (well differentiated), grade II (moderately differentiated), grade III (poorly 
differentiated) and grade IV (undifferentiated).  
Comorbidity score 
In order to adjust for comorbidities, a comorbidity index is calculated using validated 
algorithms and helps to control for disease burden in patients. The initial Charlson comorbidity 
score is a weighted score based on identified comorbid conditions (Charlson, Pompei, Ales, & 
MacKenzie, 1987). It has been adapted by Richard Deyo and Patrick Romano for use with 
administrative data (Deyo, Cherkin, & Ciol, 1992; Romano, Roos, & Jollis, 1993). The 
comorbidity index has been updated by the National Cancer Institutes which is a cancer-specific 
index including 14 conditions which excludes solid tumors, leukemias, and lymphomas 
(Klabunde, Legler, Warren, Baldwin, & Schrag, 2007).  
For this study, inpatient and outpatient claims files were used to extract claims with 
comorbid diagnoses. Claims were searched for 24 month prior to CRC diagnosis using 
International Classification of Disease 9th revision (ICD-9) diagnosis codes and ICD-9 procedure 
codes. Because diabetes is the exposure of interest in this study, diabetes diagnosis codes were 
excluded. A comprehensive list of conditions and corresponding definition and codes can be 
found in Table 12, Appendix A. When using the outpatient claims, a rule-out macro is submitted 
to avoid overestimation of diagnoses listed to “rule-out” conditions. Thus, in order to consider a 
diagnosis from the outpatient claims, this diagnosis must appear at least two times in two 
different claims separated by more than 30 days. In contrast, a diagnosis can appear only once in 
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the hospital claims to be considered. All the claims files were prepared based on the data source 
(MEDPAR or OUTPAT) and called on by a SAS macro to calculate the comorbidity score. The 
final comorbidity scores were grouped to: no comorbidity, 1 comorbidity, and 2 or more 
comorbidities.  
Section 6: Outcome and exposure variables 
Outcome variables 
Stage at diagnosis 
SEER registries record stage at diagnosis in a simplified version: localized, regional, 
distant, & unknown. For the purposes of this study, these values are combined further into a 
dichotomous variable: localized and advanced (includes regional and distant).  
Death risk  
Information about date of death is tracked in both SEER and Medicare enrollment files. 
Records were included if the patient’s month of death agreed in both files or were off by 1-3 
months.  Survival in months is recoded by the SEER program after active follow up and are 
computed using complete dates including days. At the study cutoff (December 31, 2011), vital 
status is recorded “alive” or “dead”. Patients are censored if they were “alive” at the cutoff date 






The main exposure variable under study is pre-existing diabetes status. Pre-existing 
T2DM was ascertained from the Medicare inpatient and outpatient claims using a validated 
algorithm developed by Hebert and colleagues (Hebert et al., 1999a). This algorithm provides 
high sensitivity (90.4%), specificity (95.1%) and positive predictive value. To identify diabetes 
and diabetes severity status ICD-9 codes, the algorithm looks at the interval of two years prior 
and three months after CRC diagnosis if it appears in a single hospital claim or two or more 
outpatient claims separated by more than 30 days to avoid “rule out” diagnoses. Table 2 lists the 
diagnosis codes used to identify diabetes with and without complications. Patients were 
identified as having pre-existing diabetes if they had any of the diabetes ICD-9 codes irrespective 
of complication status. Medication was not included in the algorithm for identifying patients with 





Table 2. Diabetes ICD-9 Codes by Diabetes Severity Status 
Condition Reference 
Period 
ICD-9 codes Number / Type of 









250.00, 250.01, 250.02, 250.03, 
250.10, 250.11, 250.12, 250.13, 
250.20, 250.21, 250.22, 250.23, 
250.30, 250.31, 250.32, 250.33 
At least 1 inpatient 









250.40, 250.41, 250.42, 250.43, 
250.50, 250.51, 250.52, 250.53, 
250.60, 250.61, 250.62, 250.63, 
250.70, 250.71, 250.72, 250.73, 
250.80, 250.81, 250.82, 250.83, 
250.90, 250.91, 250.92, 250.93, 
357.2, 362.01, 362.02, 362.03, 
362.04, 362.05, 362.06, 366.41 
At least 1 inpatient 
or 2 outpatient 
claims 
 





Section 7: Statistical analyses  
Descriptive analyses 
Descriptive analyses include frequency tables of colorectal cancer cases characteristics by 
diabetes status and diabetes complications status. Chi-square tests assessed differences between 
groups for categorical variables.  
Statistical models 
Logistic regression 
The association between diabetes and advanced stage of diagnosis compared to localized 
CRC stage is examined by the logistic regression models. The Multivariate logistic regression 
models are controlled for socio-demographic and clinical characteristics. SAS PROC LOGIT 
procedure is used to estimate the odds ratios and generate the 95% confidence intervals (CI).  
Kaplan Meier survival curve 
Survival curves by diabetes status are plotted using the Kaplan Meier function. 
Significant difference in survival curves is tested with the Log-Rank test with the SAS 
LIFETEST Procedure. 
Cox proportional hazards model 
The Cox proportional hazards regression generated hazard ratios (HR) of death for CRC 
cases by diabetes and diabetes with complications status while controlling for relevant 
confounders. Risk of death is calculated for all-cause mortality and cancer-specific cause of 
death. Models are generated in an iterative fashion starting with the univariate model and adding 
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other covariates while monitoring the model goodness of fit. The full multivariate model 
includes the relevant covariates. Tied data were adjusted using the Efron approximation. The 
95% confidence intervals (CI) for the HRs were generated.  






CHAPTER 4: RESULTS 
Section 1: Descriptive Analyses 
After applying the inclusion and exclusion criteria, a total of 93,710 colorectal 
cancer (CRC) patients diagnosed between 2002 and 2011 remained for the analyses. 
Cohort overall characteristics 
The mean age of the study population was 78 years and the median was 77 (Standard 
deviation (SD) = 7; range 67 to 108). The majority of patients were aged between the 67 and 85 
age group. There were slightly more females than males (55% vs. 45% respectively). The 
predominant race/ethnicity was White (78%) followed by Black (9%) and Hispanic (6%). 
Subjects were mostly either married (49%) or widowed (32%). Only 8% of the cohort lived in 
high poverty level census tracts (Table 3). 
A quarter of the cohort had one or more comorbidities (19% had one comorbidity and 6% 
had two or more comorbidities). Patients were more likely to be diagnosed at an advanced stage 
(50% at regional and distant combined). Half the subjects were diagnosed with tumors in the 
proximal area of the colon (cecum to splenic flexure). More patients had moderately 
differentiated tumors (61%) (Table 4). 
Cohort characteristics by diabetes status 
Among the study subjects, 22,155 (24%) had diabetes prior to CRC diagnosis. Patients with 
diabetes were more likely to be in the 67 to 75 years of age bracket compared to those without pre-
existing diabetes (45% vs. 41% respectively). There were slightly more female patients without 
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diabetes than with diabetes (55% vs. 53% respectively). The distribution of diabetes by 
race/ethnicity was significantly different. The proportion of diabetes was higher among non-Whites 
compared to Whites; 12% vs 8% for Blacks; 8% vs 5% for Hispanics and 6% vs 5% for 
Asian/Pacific Islanders. Marital status was evenly distributed among diabetic and non-diabetic 
patients. Significantly more diabetic patients lived in medium to high poverty areas compared to 
non-diabetics (21% vs 18% respectively lived in medium poverty level areas and 10% vs 7% 
lived in high poverty level areas) (Table 3). In terms of clinical characteristics, diabetic patients 
were more likely to have at least one comorbidity (26% vs 17%) and two or more comorbidities 
(12% vs 4%) compared to non-diabetic patients. No substantial differences were found in terms 
of CRC stage at diagnosis and grade among patients by diabetes status. More diabetic patients 
were diagnosed with CRC in the proximal colon (52% vs 49%) and less at the rectum area (21% 





Table 3. Demographic Distribution of the Colorectal Cancer Cohort by Diabetes Status 
 
 Total (%) No Diabetes (%) Diabetes (%) P value 
Patient Demographics 93710 71555 (76) 22155 (24)  
Age        <.0001 
67-75 39364 (42) 29471 (41) 9893 (45)  
        
76-85 40137 (43) 30589 (43) 9548 (43)  
86+ 14209 (15) 11495 (16) 2714 (12)  
         
Sex        <.0001 
Male 42626 (45) 32104 (45) 10522 (47)  
        
Female 51084 (55) 39451 (55) 11633 (53)  
         
Race/Ethnicity        <.0001 
White NH 74931 (78) 58645 (82) 16286 (74)  
        
Black NH 8217 (9) 5488 (8) 2729 (12)  
        
Hispanic 5180 (6) 3461 (5) 1719 (8)  
     
American Indian/Alaska 266 (0) 174 (0) 92 (0)  
Native         
Asian or Pacific Islander 4745 (5) 3479 (5) 1266 (6)  
     
Unknown 371 (0) 308 (0) 63 (0)  
         
Marital Status        0.0052 
Single 7631 (8) 5824 (8) 1807 (8)  
        
Married 45572 (49) 34941 (49) 10631 (48)  
        
Separated / divorced 6563 (7) 4892 (7) 1671 (8)  
        
Widowed 29792 (32) 22720 (32) 7072 (32)  
        
Unknown 4152 (4) 3178 (4) 974 (4)  
         
Poverty Level        <.0001 
0%-<5% poverty 43276 (46) 34076 (48) 9200 (42)  
         
5% to <10% poverty 24800 (26) 18804 (26) 5996 (27)  
        
10% to <20% poverty 17331 (18) 12728 (18) 4603 (21)  
        
20% to 100% poverty 7801 (8) 5551 (7) 2250 (10)  
      
Unknown 502 (1) 396 (1) 106 (0)  
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Table 4. Clinical Characteristics of the Colorectal Cancer Cohort by Diabetes Status 
 Total (%) No Diabetes (%) Diabetes (%) P value 
Total patients 93710 71555 (76) 22155 (24)  
Comorbidities       <.0001 
No comorbidity 70023 (75) 56397 (79) 13626 (62)  
        
One comorbidity 18031 (19) 12213 (17) 5818 (26)  
        
Two or more comorbidities 5656 (6) 2945 (4) 2711 (12)  
        
CRC stage       <.0001 
Localized 41785 (45) 31766 (44) 10019 (45)  
        
Regional 34037 (36) 25854 (36) 8183 (37)  
        
Distant 13513 (14) 10554 (15) 2959 (13)  
        
Unknown stage 4375 (5) 3381 (5) 994 (5)  
        
CRC site       <.0001 
Proximal 46896 (50) 35413 (49) 11483 (52)  
        
Distal 21236 (23) 15958 (22) 5278 (24)  
        
Rectum 22712 (24) 17990 (25) 4722 (21)  
        
Colon, NOS 2866 (3) 2194 (3) 672 (3)  
        
Grade       <.0001 
Well differentiated 8312 (9) 6360 (9) 1952 (9)  
       
Moderately differentiated 57464 (61) 43529 (61) 13935 (63)  
        
Poorly differentiated 15361 (16) 11818 (17) 3543 (16)  
        
Undifferentiated 1392 (1) 1055 (1) 337 (2)  
       
Unknown grade 11174 (12) 8788 (12) 2386 (11)  
        
Histology 0.0003 
Adenocarcinomas 80066 (85) 60987 (85) 19079 (86)   
Carcinomas 11194 (12) 8624 (12) 2570 (12)   






Distribution by diabetes complication status 
Among the diabetic group, 3,827 patients (17%) had diabetes related complications 
(neuropathy, nephropathy, retinopathy or peripheral circulatory disorders). Patients who had 
pre-existing diabetes with complications were more likely to be males, of non-White 
race/ethnicity, unmarried, have one or more comorbidities, and with tumors at the proximal area 
of the colon. There were no significant differences for poverty level, stage at diagnosis or grade 
(Table 5, 6). 
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Table 5. Demographic Characteristics by Diabetes Complication Status 
   With   Without  
 Diabetes (%) complications (%) complications (%) 
Total patients 22155 (24) 3827 (17) 18328 (83) 
Age        
67-75 9893 (45) 1720 (45) 8173 (45) 
76-85 9548 (43) 1672 (44) 7876 (43) 
86+ 2714 (12) 435 (11) 2279 (12) 
Sex        
Male 10522 (47) 1875 (49) 8647 (47) 
Female 11633 (53) 1952 (51) 9681 (53) 
Race/Ethnicity        
White NH 16286 (74) 2622 (69) 13664 (75) 
Black NH 2729 (12) 627 (16) 2102 (11) 
Hispanic 1719 (8) 323 (8) 1396 (8) 
American Indian/Alaska Native 92 (0) 22 (0) 70 (0) 
     
Asian or Pacific Islander 1266 (6) 222 (6) 1044 (6) 
Unknown 63 (0) <11 52 (0) 
Marital status        
Single (never married) 1807 (8) 344 (9) 1463 (8) 
Married 10631 (48) 1701 (44) 8930 (49) 
Separated / divorced 1671 (8) 335 (9) 1336 (7) 
Widowed 7072 (32) 1277 (33) 5795 (32) 
Unknown 974 (4) 170 (4) 804 (4) 
Poverty level        
0%-<5% poverty 9200 (42) 1568 (41) 7632 (42) 
5% to <10% poverty 5996 (27) 1014 (27) 4982 (27) 
10% to <20% poverty 4603 (21) 800 (21) 3803 (21) 
20% to 100% poverty 2250 (10) 422 (11) 1828 (10) 








Table 6. Clinical Characteristics by Diabetes Complication Status 
  With Without 
  complication complication 
 Diabetes (%) (%) (%) 
Total patients 22155 (24) 3827 (17) 18328 (83) 
Comorbidities    
No comorbidity 13626 (62) 1510 (39) 12116 (66) 
One comorbidity 5818 (26) 1225 (32) 4593 (25) 
Two or more comorbidities 2711 (12) 1092 (29) 1619 (9)  
    
CRC stage         
Localized 10019 (45) 1768 (46) 8251 (45)  
Regional 8183 (37) 1351 (35) 6832 (37)  
Distant 2959 (13) 507 (13) 2452 (13)  
Unknown stage 994 (5) 201 (5) 793 (4)  
CRC site         
Proximal 11483 (52) 2063 (54) 9420 (51)  
Distal 5278 (24) 915 (24) 4363 (24)  
Rectum 4722 (21) 726 (19) 3996 (22)  
Colon, NOS 672 (3) 123 (3) 549 (3)  
Grade         
Well differentiated 1952 (9) 353 (9) 1599 (9)  
Moderately differentiated 13935 (63) 2376 (62) 11559 (63)  
Poorly differentiated 3543 (16) 604 (16) 2939 (16)  
Undifferentiated 337 (2) 56 (1) 281 (2)  
Unknown grade 2386 (11) 437 (11) 1949 (11)  
Histology 
Adenocarcinomas 80066 (85) 76769 (85) 3297 (86) 
Carcinomas 11194 (12) 10755 (12) 439 (11) 






Section 2: Statistical Models 
Logistic Regression Analyses 
Logistic regression models assessed the association of pre-existing diabetes and higher 
odds of advanced stage at diagnosis. The univariate model and the model with addition of age as 
a covariate showed lower odds of advanced stage at diagnosis in patients with diabetes 
complications compared to patients without diabetes (odds ratio (OR) = 0.92; 95% CI = 0.86-
0.98 and OR = 0.91; 95% CI = 0.85-0.98 respectively) compared to patients with no history of 
diabetes (Table 7, Model 1-2). In the multivariate models, there was no significant increased 
odds of advanced stage of CRC based on pre-existing diabetes (Table 7, Models 3-4). 
Stratification by race did not affect the results (Table 7, Models 5-7). Similarly, stratification by 
sex showed no association of diabetes and CRC stage for both men and women (Table 7, 
Models 8-9). Other factors that increase the odds of being diagnosed at an advanced stage of 
CRC compared to localized stage include high poverty level, non-White race, and cancers with 





Table 7. Logistic Regression Models 
Regression 
Models 
Diabetes without Complications Diabetes with Complications 
OR 
Lower 





Model 1 0.98 0.95 1.02 0.92 0.86 0.98 
Model 2 0.98 0.95 1.01 0.91 0.86 0.98 
Model 3 1.00 0.97 1.04 1.00 0.94 1.07 
Model 4 0.99 0.95 1.02 0.97 0.91 1.04 
Stratified by race 
Model 5 1.01 0.88 1.15 0.92 0.72 1.19 
Model 6 1.02 0.92 1.14 1.01 0.84 1.21 
Model 7 
0.98 0.94 1.02 0.95 0.88 1.04 
Stratified by sex 
Model 8 0.97 0.92 1.02 0.93 0.84 1.03 
Model 9 0.98 0.93 1.03 0.99 0.89 1.09  
OR: Odds ratio, CI: confidence interval 
Model 1: Univariate with diabetes only  
Model 2: model 1 + age 
Model 3: Model 2 + comorbidity  
Model 4: full model (model 3 + race, marital status, poverty level, histology, grade, registry, year 
of diagnosis and cancer site).  
Model 5: full model stratified by race, Hispanics 
Model 6: full model stratified by race, Blacks 
Model 7: full model stratified by race, Whites 
Model 8: full model stratified by sex, males 









Over the study period (2002-2011), 44,688 (48%) subjects died of all causes and 26,037 
(28%) died from CRC. Among patients without diabetes, 47% died of all causes and 28% died 
from CRC. Patients with pre-existing diabetes with complications died at a higher percentage of all-
cause mortality compared to those with diabetes without complications (56% vs. 49%), however, 
there were no differences in proportion of death for CRC cause-specific mortality (Table 8). 
 
Table 8. Distribution of CRC Deaths by Diabetes Status 
   Diabetes Status  
    Diabetes with 
 Total deaths  Diabetes without Complications 
Mortality (%) No Diabetes (%) complications (%) (%) 
Overall mortality 44688 (48) 33510 (47) 8905 (49) 2273 (56) 
CRC cause-specific 






The median survival months for overall mortality was 61 months (95% CI = 60-62). The 




Kaplan Meier survival curves 
Survival curves were generated for overall survival and for survival from CRC by 
diabetes status: no diabetes (blue line), diabetes without complications (red line), and diabetes 
with complications (green line). Diabetes with complications had the most unfavorable crude 
survival rates followed by those with diabetes without complications (log-rank test P-value 
<0.0001) (Figure 1). Similarly, diabetes with complications contributed to lowest CRC specific 
survival rate (log-rank test P-value <0.0001), however; there were no differences between non-

























Figure 1. Crude total survival curve by diabetes status. 0: no diabetes; 1: diabetes without complications; 































Figure 2. Crude CRC cancer-specific survival curve by diabetes status. 0: no diabetes; 1: diabetes 
without complications; 2: diabetes with complications 
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Cox proportional hazards regression analyses 
In the univariate Cox regression model, CRC patients with diabetes have 21% increased 
risk of total mortality (hazard ratio (HR) = 1.21; 95% CI = 1.18-1.23). The mortality risk is 
particularly higher among diabetic patients with complications (HR = 1.69; 95% CI = 1.62-1.76) 
(Table 9, Model 1). Significant results were only observed for diabetes with complications in 
colorectal cancer specific-cause mortality (HR = 1.14; 95% CI = 1.07-1.22). Similar results were 
observed when adjusted for age and comorbidities, although the effects were reduced after the 
introduction of comorbidities (Table 9, Model 2-3). 
The fully adjusted model was controlled for age, sex, marital status, race/ethnicity, 
poverty level, comorbidities, stage, histology, grade, year of diagnosis, and registry. Colorectal 
cancer patients in the fully adjusted model were more likely to die of all cause if they were 
diagnosed with diabetes prior to their CRC diagnosis particularly those with complications 
compared to those with no prior diabetes diagnosis (HR = 1.20; 95% CI = 1.17-1.23 for diabetes 
and HR = 1.47; 95% CI = 1.34-1.54 for diabetes with complications). Patients with diabetes with 
complications were 16% more likely to die of colorectal cancer compared to patients without 





Table 9. Effect of Pre-Existing Diabetes on Total Mortality and CRC Cause-Specific 
Mortality in Patients with Colorectal Cancer 



















Model 1: Univariate with diabetes 
No diabetes Referent     Referent     
Diabetes  0.99 0.96 1.02 1.21a 1.18 1.23 
Diabetes without complications 0.97 0.94 1.00 1.13 a 1.10 1.16 
Diabetes with complications 1.14 1.07 1.22 1.69 a 1.62 1.76 
Model 2: Model 1 + age 
No diabetes Referent     Referent     
Diabetes  1.02 0.99 1.05 1.27 a 1.24 1.29 
Diabetes without complications 0.99 0.96 1.02 1.18 a 1.15 1.21 
Diabetes with complications 1.18 a 1.11 1.26 1.78 a 1.71 1.86 
Model 3: Model 2 + comorbidity 
No diabetes Referent     Referent     
Diabetes  0.99 0.96 1.02 1.16 a 1.13 1.18 
Diabetes without complications 0.97 0.94 1.00 1.11 a 1.08 1.13 
Diabetes with complications 1.10 a 1.03 1.17 1.43 a 1.37 1.50 
Model 4: Fully adjusted model 
No diabetes Referent     Referent     
Diabetes  1.05 a 1.02 1.09 1.20 a 1.17 1.23 
Diabetes without complications 1.04 0.99 1.08 1.15 a 1.12 1.18 
Diabetes with complications 1.16 a 1.08 1.25 1.47 a 1.40 1.54 
  




Stratification by race/ethnicity 
Hispanic diabetic patients were more likely to die of all-cause mortality compared to 
those with no diabetes and the risk was higher for patients who had diabetes with complications 
with a 27% increased risk (HR = 1.27; 95% CI = 1.06-1.20). However, among Hispanics, 
colorectal cancer specific mortality was not affected by diabetes status. Similar findings were 
observed among Black patients. Pre-existing diabetes was a determinant of increased risk of 





Table 10. Effect of Pre-existing Diabetes on Death Risk in Patients with CRC by Race 
 


















No diabetes Referent     Referent     
Diabetes  1.04 0.91 1.18 1.14a 1.03 1.26 
Diabetes without complications 1.03 0.90 1.19 1.11a 1.00 1.24 
Diabetes with complications 1.11 0.87 1.42 1.27a 1.06 1.52 
Blacks 
No diabetes Referent     Referent     
Diabetes  0.96 0.88 1.06 1.11a 1.04 1.20 
Diabetes without complications 0.96 0.87 1.07 1.07 0.99 1.16 
Diabetes with complications 1.01 0.85 1.19 1.29a 1.15 1.45 
Whites 
No diabetes Referent     Referent     
Diabetes  1.07a 1.03 1.11 1.22a 1.18 1.25 
Diabetes without complications 1.05a 1.01 1.09 1.17a 1.13 1.20 
Diabetes with complications 1.21a 1.12 1.32 1.53a 1.45 1.62  
a statistically significant at p<0.05.  
*Stratified models are adjusted for age, sex, marital status, race/ethnicity, poverty level, 
comorbidities, histology, grade, year of diagnosis, and registry. 
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Stratification by stage 
Total mortality was affected by pre-existing diabetes for all stages. The effect was 
strongest for diabetes with complications. For instance, CRC patients diagnosed at a localized 
stage who had diabetes with complications had 77% increased risk of all mortality compared to 
patients without diabetes (HR = 1.77; 95% CI = 1.65-1.90). Similar results were observed for 
patients with regional and distant stage at diagnosis (Table 11). Overall, diabetes contributed to 
higher risk of death at 28% and 10% for localized and advanced stage respectively. 
Colorectal cancer specific mortality was significantly affected by pre-existing diabetes 
with complications at localized and advanced stages. The observed increase in CRC mortality 
was 22% for localized CRC (HR = 1.22; 95% CI = 1.05-1.41); 16% for regional stage (HR = 






Table 11. Effect of Pre-Existing Diabetes on Death Risk in Patients with CRC by Stage at 
Diagnosis 
 


















No diabetes Referent     Referent     
Diabetes  1.03 0.95 1.12 1.29a 1.24 1.35 
Diabetes without complications 1.00 0.92 1.08 1.22 a 1.17 1.27 
Diabetes with complications 1.22 a 1.05 1.41 1.77 a 1.65 1.90 
Regional 
No diabetes Referent     Referent     
Diabetes  1.03 0.98 1.09 1.18 a 1.13 1.23 
Diabetes without complications 1.00 0.94 1.05 1.12 a 1.07 1.16 
Diabetes with complications 1.16 a 1.04 1.30 1.47 a 1.36 1.58 
Distant 
No diabetes Referent     Referent     
Diabetes  1.06a 1.01 1.13 1.10 a 1.05 1.16 
Diabetes without complications 1.04 0.98 1.09 1.08 a 1.03 1.14 
Diabetes with complications 1.14 a 1.02 1.27 1.17 a 1.06 1.29 
Unknown 
No diabetes Referent     Referent     
Diabetes  1.09 0.97 1.22 1.19 a 1.09 1.31 
Diabetes without complications 1.08 0.97 1.21 1.15 a 1.05 1.26 
Diabetes with complications 0.86 0.68 1.10 1.24 a 1.05 1.47 
 
a Statistically significant at p<0.05.  
*Stratified models are adjusted for age, sex, marital status, race/ethnicity, poverty level, 
comorbidities, histology, grade, year of diagnosis, and registry. 
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CHAPTER 5: DISCUSSION 
Section 1: Study findings summary  
The aim of this study was to analyze the influence of pre-existing diabetes mellitus and 
diabetes with complications on survival and stage of diagnosis for the overall population of 
Medicare beneficiaries diagnosed with colorectal cancer between 2002 and 2011 and, 
particularly, for the Hispanic group.  
In the analytical cohort, almost one of every four colorectal cancer patients had pre-
existing diabetes and of these diabetic patients, almost one of every five patients had diabetes 
with complications. The logistic model revealed that diabetes, regardless of severity, is not 
associated with CRC stage at diagnosis on a population basis. Stratifying by race/ethnicity or sex 
did not change these results. On the other hand, the study reports that pre-existing diabetes is a 
predictor of significantly higher risk of death from all-cause mortality in elderly patients with 
CRC compared to non-diabetic cancer patients. Diabetes with complications had the poorest 
outcomes. Total mortality increased risk was not modified by race/ethnicity. Hispanic patients 
with diabetes had poorer overall survival compared to Hispanic patients without diabetes 
irrespective of diabetes severity. Diabetes was associated significantly with higher risk of total 
mortality in patients at all stages of diagnosis. Risk of colorectal cancer specific mortality among 
all patients and all stages was only increased by diabetes with complications. Diabetes did not 
affect risk of death from CRC among Hispanic patients. Overall, diabetes with complications had 
the poorest outcomes compared to diabetes without complications and no diabetes. 
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Section 2: Discussion of results 
Diabetes and effect on CRC stage of diagnosis 
The association of pre-existing diabetes and CRC stage at diagnosis has not been 
comprehensively studied in the literature. To our knowledge the current study is the first to 
assess this relationship in a cohort of American elderly patients. In this study, diabetes was not 
associated with advanced stage at diagnosis in CRC patients. Although diabetes is a known risk 
factor for colorectal cancer, it appears that having diabetes does not predict being diagnosed at a 
more advanced stage of the disease, which is known to contribute to poorer prognosis.  
Few studies examined the association of diabetes status and colorectal tumor stage 
(Siddiqui et al., 2008; van de Poll‐Franse, Lonneke V et al., 2007). Researchers from China 
found a positive association of diabetes and advanced tumor stage (Feng, Zhou, & Mao, 2011). 
These authors used a smaller sample (733 patients) from a single institution in China. In another 
earlier study from the Netherlands, authors observed a higher likelihood of advanced stage at 
diagnosis among colon cancer patients with diabetes (van de Poll‐Franse, Lonneke V et al., 
2007). However, this study used non-American subjects, assessed only colon cancer and 
combined type I and type II diabetes.  In another study, researchers observed that when patients 
have poorly controlled diabetes, they are more likely to have higher number of colonic 
adenomatous polyps, more advanced lesions and greater use of exogenous insulin compared to 
those with controlled diabetes (Siddiqui et al., 2008). In our study, we did not have information 
about diabetes control which is usually measured by Hemoglobin A1c (HbA1c) levels. 
Nonetheless, we examined whether diabetes with complications was associated with advanced 
colorectal tumors; however, we did not observe a significant association.  
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Screening is a major determinant of stage at diagnosis for colorectal cancer. Patients who 
follow the screening guidelines of CRC are more likely to detect colon polyps early-on before 
they become cancerous or detect the disease at an earlier stage when treatment is more effective. 
Although CRC screening in the US is not optimal, it seems as diabetic patients might have more 
opportunities to interact with physicians in the course of diabetes management and potentially 
receive CRC screening recommendations from their care providers. For instance, authors found a 
dose-response relationship between having multiple morbidities- including diabetes- and a 
greater likelihood of adherence to CRC screening (Fleming, Steven T. et al). This is especially 
relevant among primary care physicians as they are increasingly incentivized to increase their 
CRC screening recommendations by the Centers of Medicare and Medicaid Services in the 
context of clinical quality measures improvement (Rosenthal, Fernandopulle, Song, & Landon, 
2004) .  
Although researchers observed higher number of physician visits among diabetic patients 
compared to non-diabetics (van de Poll‐Franse, Lonneke V et al., 2007), nonetheless, it is 
unclear whether physicians are adequately recommending CRC screening, especially, to diabetic 
patients. This study did not observe an association of diabetes and CRC stage at diagnosis for 
both men and women. However, the literature seems to indicate that there are differences by 
gender in CRC screening among diabetic patients. For instance, it was found that elderly women 
with diabetes are actually less likely to receive CRC screening compared to women without 
diabetes (McBean & Yu, 2007). Yet, in another study, authors found that older men were more 
likely to be up to date with CRC screening, as indicated in the guidelines, if they had diabetes 
than if they did not (Miller, Tarasenko, Parker, & Schoendorf, 2014). Therefore, the relationship 
of diabetes and CRC screening needs to be examined further and physicians treating diabetic 
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patients need to promote recommended screenings to their patient population during routine 
visits.  
Diabetes and risk of overall death 
This study found a significant association between pre-existing diabetes and all-cause 
mortality in a cohort of elderly patients with colorectal cancer. These results are in agreement 
with some previous studies with an HR ranging from 1.23-1.42 (Bella et al., 2013; Gross et al., 
2006a; Y. Huang, Lin, Chen, Lin, Yang, Jiang, Chang, Lan, Wang, & Liu, 2011; Jullumstr, 
Kollind, Lydersen, & Edna, 2009; Luo, Lin, He, & Hendryx, 2014; Meyerhardt et al., 2003a; 
Polednak, 2006; van de Poll‐Franse, Lonneke V et al., 2007). In our study, we found a significant 
HR of 1.20 for overall mortality for diabetics compared to non-diabetics. In a population based 
study, Gauss et al. found a 23% increase in risk from all-cause mortality in patients with 
comorbid diabetes (Gross et al., 2006a). Patients in a clinical trial had poorer prognosis if they 
had diabetes at colorectal cancer diagnosis with a 42% increased risk of overall death 
(Meyerhardt et al., 2003a). Similarly, patients from the Connecticut cancer registry were found 
to have a 38% elevated risk of death from any cause (Polednak, 2006). Bella et al. found a 41% 
increased risk of all-cause mortality among adult Italian diabetic patients irrespective of sex or 
subsite (Bella et al., 2013).  
Other evidence that used a systematic review of identified articles reported similar 
results. In a meta-analysis, Barone et al. observed 41% increase in risk of overall mortality in 
patients with pre-existing diabetes compared to patients without a history of diabetes from the 
analysis of 23 studies (Barone et al., 2008).  Another meta-analysis from 15 articles found that 
compared to those without diabetes mellitus, persons with pre-existing diabetes had poorer 
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prognosis in terms of short and long term mortality with a 32% increase in all-cause mortality 
(Stein et al., 2010)  
In contrast to most findings, some studies did not observe a significant relationship 
between a history of diabetes and overall mortality (Chen et al., 2010; C. Huang et al., 2012; 
Jullumstr et al., 2009). However, these studies had non-US subjects, used small samples, used 
subjects restricted to one institution, examined short term survival, and did not adjust for relevant 
confounders. 
Diabetes and risk of colorectal cancer death 
In the present study, although we found a significant association between pre-existing 
diabetes and colorectal cancer specific cause of death, the effect was minimal (HR = 1.051, 95% 
CI = 1.016-1.087). In the current literature, the association of pre-existing diabetes with 
colorectal cancer cause of death is not clear. For instance, a study found a significant impact on 
colon specific survival among Taiwanese patients who had diabetes. These findings were 
particularly significant in patients with advanced stage (Y. Huang, Lin, Chen, Lin, Yang, Jiang, 
Chang, Lan, Wang, & Liu, 2011). Researchers from Italy found also a significant relationship 
between diabetes and colorectal cancer death (HR 1.36; 95 % CI = 1.11–1.67) in patients 15 
years and older (Bella et al., 2013). In a meta-analysis, the authors found a 12% increased risk of 
colorectal cancer-specific mortality in diabetic patients compared to their non-diabetic 
counterparts from the analysis of 26 manuscripts (Mills, Bellows, Hoffman, Kelly, & Gagliardi, 
2013). Patients in the Cancer Prevention Study-II Nutrition Cohort were more likely to die of 
CRC if they had comorbid diabetes (RR = 1.29; 95% CI = 0.98-1.70) (Dehal et al., 2011). In 
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contrast, other researchers did not find elevated risk in cause of death from CRC among diabetic 
patients (Polednak, 2006; Stein et al., 2010). 
The effect of diabetes with complications on CRC prognosis 
In our study, we found a more pronounced effect on colorectal cancer mortality, both 
overall and cause-specific, in those who had diabetes with complications (neuropathy, 
nephropathy, retinopathy or peripheral circulatory disorders). We observed almost a 50% 
increase in risk of death from all causes and a 16% increase in CRC specific death. These 
findings are unique as most studies did not distinguish diabetes status by severity (Bao et al., 
2010; Bella et al., 2013; Dehal et al., 2011; Feng et al., 2011; Gross et al., 2006a; Y. Huang et 
al., 2011; Jullumstr et al., 2009; Meyerhardt et al., 2003a; Meyerhardt et al., 2003b; Polednak, 




Section 3: Explanations of the main findings 
The exact reasons of how diabetes mellitus affects colorectal cancer prognosis are not 
clear; however, there are potential explanations on how diabetes might directly or indirectly 
influence increased risk of colorectal cancer mortality.  
Some physiological pathways observed, including hyperinsulinemia and hyperglycemia, 
are known factors that contribute to increased risk of colorectal carcinogenesis and tumor 
metastasis and; therefore, might also directly affect the outcomes of the disease (Bao et al., 2010; 
Giovannucci, 2007; Tsai & Giovannucci, 2012). Moreover, it has been found that diabetes 
increases risk of colorectal cancer recurrence which might contribute to poorer prognosis (Feng 
et al., 2011; Meyerhardt et al., 2003b; Mills, Bellows, Hoffman, Kelly, & Gagliardi, 2013).  
On the other hand, diabetes might increase mortality in general in association with death 
from diabetes-related diseases (e.g., stroke, ischemic heart disease, hypertension, chronic renal 
failure). For instance, in a study of multimorbidity and survival in persons with colorectal cancer, 
Gross et al. found that among CRC deaths, 9% were attributable to congestive heart failure and 
more than 5% were attributable to chronic obstructive pulmonary disease (Gross et al., 2006b). 
Another study using a large US cohort found a 2 fold increase of death from cardiovascular 
diseases among patients with self-reported diabetes and colorectal cancer (Dehal et al., 2011). 
Some other plausible explanations may generate from more indirect influence of diabetes 
in terms of the cancer management and treatment. For instance, comorbid diabetes might 
influence treatment decisions, treatment response, and treatment-related side effects. Researchers 
found that patients with diabetes were less likely to start recommended colorectal cancer 
adjuvant chemotherapy (Gross, McAvay, Guo, & Tinetti, 2007) and less likely to receive 
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aggressive cancer treatment (van de Poll‐Franse, Lonneke V et al., 2007). This might be due to 
increased cancer treatment related side-effects among diabetic patients compared to those 
without diabetes (Meyerhardt et al., 2003b).  
Diabetes with complications and CRC prognosis 
In this study, patients were more likely to die specifically of colorectal cancer if they had 
diabetes with complications. Reasons for this effect have not been fully explored. This study 
showed that, while diabetes in general or diabetes without complications is not associated with 
poorer colorectal cancer survival, when patients have diabetes with microvascular complications, 
they are more likely to die of colorectal cancer compared to non-diabetics. This might indicate 
that poor diabetes control is unfavorable for colorectal cancer patients and that controlling 
diabetes and preventing its complications might be beneficial for these patients.  
Diabetes control is usually measured by glycosylated hemoglobin (HbA1c) where levels 
of HbA1c greater than 7.5% are considered unsatisfactory glycemic control and patients are 
referred to medication use to control diabetes (Woerle et al., 2007). A common medication used 
in diabetes control is Metformin which aids to decrease plasma glucose levels by increasing 
intracellular glucose uptake (Dodd et al., 2009). Researchers demonstrated that colorectal cancer 
patients who control their blood glucose using metformin experience a 30% improvement in 
overall survival compared to other agents (Garrett et al., 2012).  
In our study we were not able to assess the effect of diabetes control on CRC outcomes as 
this information is not available; however, diabetes with complications can be considered a 
proxy to poor diabetes control as research shows that uncontrolled diabetes is an independent 
risk factor for diabetes complications (Stratton et al., 2006). Clinicians have a great role in aiding 
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their patients to manage their diabetes through regular HbA1c testing, education about lifestyle 
changes and medication. For instance, it has been demonstrated that cancer patients who receive 
diabetes education are less likely to visit emergency departments, have fewer hospital admissions 
and are more likely to manage their diabetes with more frequent HbA1c tests (Irizarry et al., 
2013).  
Effect of diabetes on CRC prognosis by stage 
Colorectal cancer specific mortality was significantly affected by pre-existing diabetes 
with complications at localized, regional and distant stages compared to no diabetes but not 
when diabetes was present without complications. Consistent with this finding, previous 
literature reported that uncontrolled diabetes, an independent risk factor for diabetes 
complications, leads to diagnosis of CRC at later stages and poorer 5-year survival (Siddiqui et 
al., 2008; Stratton et al., 2006). Further, Huang and colleagues found that diabetic patients 
diagnosed at an advanced stage were particularly at significant higher risk of dying of colon 
cancer; although, they did not examine the relationship by diabetes complications status (Y. 
Huang, Lin, Chen, Lin, Yang, Jiang, Chang, Lan, Wang, & Liu, 2011). Our study shows that 
diabetes with complications is detrimental to CRC patients regardless of what stage they are 
diagnosed at. The exact mechanism for this finding is uncertain and further research is needed.  
Effect of diabetes on CRC prognosis for Hispanics  
Hispanics with colorectal cancer and pre-existing diabetes, particularly those who had 
diabetes with complications, were significantly more likely to die of overall causes compared to 
Hispanics without diabetes. The relationship was attenuated for mortality from colorectal cancer.  
The effect of diabetes on CRC mortality among Hispanics has not been examined in the 
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literature. In general, Hispanics have higher prevalence of diabetes with a substantial increase in 
the last decades (Geiss et al., 2014). Moreover, while mortality from diabetes is decreasing in 
other non-Hispanic racial/ethnic groups, it is on the rise for Hispanics (McBean, Li, Gilbertson, 
& Collins, 2004). Further, Hispanics have poorer survival from colorectal cancer compared to 
non-Hispanic Whites, especially when more precise follow-up procedures are used (Pinheiro et 
al., 2011).  
Hispanics who suffered from diabetes complications were substantially more likely to die 
compared to patients without complications or no diabetes. Rising literature documents that 
Hispanics suffer disproportionately from diabetes complications which is likely to contribute to 
unfavorable cancer survival. Karter and colleagues reported that Hispanic members of Kiser 
Permanente were more likely to have diabetes complications compared to other groups, 
particularly, End Stage Renal Disease (ESRD) (Karter et al., 2002). Similarly, a systematic 
review observed an increased risk of ESRD and retinopathy among Hispanics in the US 
(Lanting, Joung, Mackenbach, Lamberts, & Bootsma, 2005). Other diabetes related 
complications that affect Hispanics disproportionately are amputations (Lavery et al., 1996).  
Reasons for the higher proportions of diabetes complications among Hispanics is 
potentially due to less than optimal diabetes care and control. For instance, Hispanics are less 
likely to self-monitor their blood glucose as recommended by the American Diabetes 
Association (ADA) to monitor once daily when diabetes is treated with medications (Karter, 
Ferrara, Darbinian, Ackerson, & Selby, 2000). Compared to non-Hispanic Whites, Hispanics are 
less likely to treat their diabetes with diet and exercise (61% vs 36% respectively) and have 
lower proportions of annual eye examination (73% vs 49% respectively) (Coronado, Thompson, 
Tejeda, Godina, & Chen, 2007). Although health disparities among Hispanics are usually 
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attributed to poor access to care (Velasco-Mondragon, Jimenez, Palladino-Davis, Davis, & 
Escamilla-Cejudo, 2016), in our study all subjects were covered under Medicare and thus, access 
to care is unlikely a contributor to poor outcomes. Nevertheless, access to care is not always 
synonymous to quality of care. Disparities in quality of care among Medicare beneficiaries are 
not uncommon (Schneider, Zaslavsky, & Epstein, 2002). Moreover, lack of English language 
fluency plays a role in health care access and is likely a predictor for poor diabetes care for 
Hispanics. As it is documented that diabetes education is crucial to better diabetes management 
especially when diabetes is comorbid to cancer (Irizarry et al., 2013), it becomes imperative that 
Hispanics with CRC receive culturally competent diabetes education programs in order to 




Section 4: Strengths and Limitations 
Strengths 
The strength of this study lies in the inclusion of large number of patients in the analysis 
from a nationally representative database. The SEER-Medicare data are widely used in research 
and offer a combination of clinical information from the cancer registries and diagnoses and 
procedures from the Medicare claims data. These data are population-based and allow authors to 
track patients longitudinally with the possibility to follow patients from their enrollment in the 
Medicare program until their death regardless of place of residency.  
Limitations 
Findings from this study have to be interpreted in light of certain limitations. 
Administrative and surveillance data are not inherently designed for research. Some important 
information lack and is likely to affect to some degree the magnitude of the effects. For example, 
many behavioral and patient characteristics such as obesity status, smoking, red meat and alcohol 
consumption, individual-level income brackets, physical activity level, and family history of 
CRC were missing. These factors are all related to diabetes and colorectal cancer outcomes. If 
patients who had diabetes also had heavy smoking and alcohol intake, had high BMI and other 
unfavorable characteristics, then the observed increased mortality associated with diabetes might 
be overestimated. Although we were unable to control for these factors, other studies that did 
control, did not observe a weakening in the association between diabetes and increased risk of 
overall and cancer specific death (Coughlin et al., 2004; Dehal et al., 2011). Moreover, since we 
controlled for comorbidities, most of the factors that were not included are covered in the 
comorbidities variable.  
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An important factor we were unable to account for is duration of diabetes; however, 
Dehal et al. did not find significant differences in CRC prognosis based on duration of diabetes 
(Dehal et al., 2011). Another limitation is related to the identification of diabetic patients from 
claims data. This limitation has two levels, first the accuracy of the algorithm used to identify 
pre-existing diabetes in the time frame set before CRC diagnosis. There is likelihood to miss 
some cases of diabetes if they did not have an encounter with their clinicians either at an 
outpatient or inpatient setting. To mitigate this limitation we allowed a long period of time of 24 
months before CRC diagnosis and 3 month after to include previously undiagnosed diabetes 
(Yang et al., 2013), in addition, we used a validated algorithm with sensitivity of 74.4% and 
specificity of 97.5% (Hebert et al., 1999b) to identify patients with diabetes. Second, we do not 
have information on cases with prediabetes (impaired fasting glucose and/or impaired glucose 
tolerance) and our hazard ratios might be underestimated. This remains a concern as the 
prevalence of prediabetes is on the rise (Boyle, Thompson, Gregg, Barker, & Williamson, 2010).  
Another concern is related to using Medicare data which tracks claims for patients 65 and 
older and previous medical history is unavailable for this patient population in addition to the 
restriction to non-HMO enrollees. This limitation affects the generalizability of the findings 
which are restricted to older persons aged 65 and older enrolled in Medicare Fee For Service 
plans. Nevertheless, the elderly population is the most affected by diabetes and CRC and the 
literature indicates that the elderly SEER population is similar in terms of demographic 
characteristics to the rest of the US elderly population (Warren et al., 2002).  
Another clinical factor we have not controlled for is treatment. Reasons for this reside in 
unavailability of all the treatment variables in the dataset, only first course surgery and 
radiotherapy are recorded while chemotherapy is not. In addition, these variables are not reliable 
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as the data was missing for a large number of patients where the values are listed as “unknown 
whether surgery or radiation were performed”. Moreover, treatment is usually done according to 
guidelines based on cancer stage. Since one of the exposures in the study is the diabetes with 
complications, this would have a significant impact on the choice of therapy. It is not customary 
for surveillance data to contain detailed therapy information especially when other pathologies 
are present. Lastly, the findings did not take into consideration use of diabetes medication as this 
data was not available for the full study period. However, researchers found no difference in 
CRC deaths among those who have diabetes and use insulin compared to those with no reported 




CHAPTER 6: CONCLUSION 
This study contributes to the existing evidence about the association of pre-existing 
diabetes and mortality from colorectal cancer. It also adds to some knowledge gaps in terms of 
the relationship of diabetes complications and CRC survival; the relationship in terms of the 
association of pre-existing diabetes with advanced stage at diagnosis of CRC and the variation by 
race/ethnicity. In addition, the findings also underscore lack of understanding of the underlying 
mechanisms of how diabetes affects CRC outcomes.  
In summary, this study used population-based data and the findings indicate that pre-
existing diabetes contributes to poorer overall survival in patients with colorectal cancer and 
increased mortality from CRC in diabetes with complications. These results extended to the 
Hispanic group, a focus population in this study. Pre-existing diabetes is not associated with 
advanced stage at diagnosis in patients with colorectal cancer, however, diabetes with 
complications is unfavorable for survival from CRC for patients at all stages of diagnosis. These 
findings are relevant in the context of continuous increase in prevalence of diabetes among the 
aging US population. Because these diseases are more prevalent among the elderly, this group is 
more likely to have both diseases at the same time and more clinicians will need to develop care 
plans that are interdisciplinary and take into consideration the added burden of diabetes among 
CRC patients.  
Particular attention is needed for patients with diabetes complications as they suffer from 
the worst outcomes. Increased focus on diabetes education, diabetes self-management and 
improved diabetes control are critical to improve survival in colorectal patients with comorbid 
diabetes. Diabetic patients may also benefit from earlier colorectal screening to reduce both the 
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incidence of CRC and improve CRC outcomes. New guidelines of CRC screening are warranted 





Table 12. NCI Comorbidity Index Conditions and Codes 
Condition Definition/Codes 
Acute Myocardial Infarction ICD-9 Diagnosis: 410.xx with inpatient length of stay >2 days 
History of Myocardial 
Infarction ICD-9 Diagnosis: 412.bb 
Congestive Heart Failure ICD-9 Diagnosis: 398.91, 425.4x-425.5x, 425.7x-425.9x, 428.xx 
Peripheral Vascular Disease 
ICD-9 Diagnosis: 093.0x, 440.xx-441.xx, 442.0x-442.8x, 443.1x-
443.9x, 447.70-447.73, 785.4x, V43.4x 
ICD-9 Procedure: 00.60, 38.13, 38.14, 38.15, 38.16, 38.18, 38.33, 




ICD-9 Diagnosis: 430.xx- 438.xx 
ICD-9 Procedure: 00.61, 00.62, 00.63, 00.65, 38.12, 38.32, 38.42, 
39.22, 39.28, 39.74 
Chronic Obstructive 
Pulmonary Disease (COPD) 
ICD-9 Diagnosis: 416.8x-416.9x, 490.xx-496.xx, 500.xx-505.xx, 
506.4x, 519.1x 
Dementia 
ICD-9 Diagnosis: 290.xx, 291.0x-291.2x, 292.82, 294.1x, 331.0x-
331.2x, 331.82 
Paralysis (Hemiplegia or 
Paraplegia) ICD-9 Diagnosis: 342.xx, 344.0x-344.6x, 344.9x 
Renal Disease 
  
ICD-9 Diagnosis: 403.01, 403.11, 403.91, 404.02, 404.03, 404.12, 
404.13, 404.92, 404.93, 582.xx-583.xx, 585.xx-586.xx, 588.xx, 
V42.0x, V45.1x, V56.xx 
ICD-9 Procedure: 39.27, 39.42, 39.95, 54.98, 55.69 
Mild Liver Disease ICD-9 Diagnosis: 070.32-070.33, 070.54, 571.2x, 571.4x-571.6x 
Moderate/Severe Liver 
Disease 
ICD-9 Diagnosis: 070.22-070.23, 070.44, 456.0x-456.2x, 572.2x-
572.8x, V42.7x 
ICD-9 Procedure: 39.1b, 42.91, 50.5x 
Peptic Ulcer Disease ICD-9 Diagnosis: 531.xx-534.xx 
Rheumatologic Disease 
ICD-9 Diagnosis: 710.0x, 710.1x, 710.4x, 714.0x-714.2x, 714.81, 
725.bb 
AIDS ICD-9 Diagnosis: 042.xx-044.x, V08.bb, 795.71 
NCI: National Cancer Institute 
”b” denotes blank 
”x” denotes any character including blank 




Table 13. The Association of Diabetes and Stage at Diagnosis for CRC 
Model variables Odds Ratio 
95% Confidence Interval  
Lower limit Upper limit 
Diabetes status 
No diabetes Referent     
Diabetes without complications 0.98 0.94 1.01 
Diabetes with complications 0.96 0.90 1.03 
Age 
67-75 Referent     
76-85 0.94 0.91 0.97 
86+ 0.88 0.84 0.92 
Comorbidities 
No comorbidity Referent     
One comorbidity 0.91 0.88 0.94 
Two or more comorbidities 0.72 0.67 0.76 
Poverty level 
0%-<5% poverty Referent     
5% to <10% poverty 1.05 1.01 1.09 
10% to <20% poverty 1.06 1.02 1.10 
20% to 100% poverty 1.16 1.10 1.23 
Unknown 0.85 0.70 1.03 
Sex 
Male Referent     
Female 0.94 0.92 0.97 
Marital status 
Single Referent     
Married 0.93 0.89 0.98 
Separated / divorced 1.05 0.98 1.13 
Widowed 1.00 0.95 1.06 
Unknown 0.72 0.66 0.78 
Race/ethnicity 
Whites Referent     
Black NH 1.13 1.07 1.19 
Hispanic 1.14 1.07 1.21 
American Indian/Alaska Native 1.13 0.87 1.46 
Asian or Pacific Islander 1.15 1.07 1.23 
Unknown 0.32 0.24 0.42 
Histology 
Adenocarcinoma Referent     
Carcinoma 1.51 1.45 1.58 
Carcinoma NOS 2.44 2.15 2.77 
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Model variables Odds Ratio 
95% Confidence Interval  
Lower limit Upper limit 
Cancer site 
Proximal Referent     
Distal 0.99 0.95 1.02 
Rectum 0.92 0.89 0.95 
Colon, NOS 3.17 2.84 3.54 
Grade 
Well differentiated Referent     
Moderately differentiated 2.36 2.24 2.48 
Poorly differentiated 5.27 4.96 5.59 
Undifferentiated 5.29 4.65 6.02 
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